Investment Thesis
Reviva is a pre-commercial pharmaceutical company with critical financial distress: $14.4M in cash against $24.6M annual cash burn creates a 7-month runway to insolvency. Minimal revenue ($122.9K) against massive operating losses (-$20.2M) indicates unproven commercial viability and an unsustainable cost structure with high bankruptcy or dilution risk.
Strengths
- Revenue growing 81.5% YoY despite minimal base demonstrates emerging commercial traction
- Zero long-term debt eliminates refinancing risk and interest burden obligations
- Positive stockholders' equity of $8.6M provides asset base for potential restructuring or asset sales
Risks
- Critical liquidity crisis: $24.6M annual cash burn against $14.4M cash creates 7-month runway
- Unsustainable cost structure with $20.2M operating losses against $122.9K revenue (16,440% negative operating margin)
- Pre-commercial stage with unproven product viability and uncertain path to profitability
- High probability of dilutive capital raise or bankruptcy without revenue inflection or major cost restructuring
- Burn rate accelerating relative to revenue growth suggests deteriorating financial condition
Key Metrics to Watch
- Monthly cash burn rate and cash runway to depletion
- Quarterly revenue growth trajectory and gross margin emergence
- Capital raise announcements and dilution percentage to shareholders
- Operating expense reduction initiatives and path to cash flow breakeven
Financial Metrics
Revenue
122.9K
Net Income
-19.9M
EPS (Diluted)
$0.00
Free Cash Flow
-24.6M
Total Assets
15.9M
Cash
14.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-16,440.6%
Net Margin
-16,167.8%
ROE
-229.7%
ROA
-124.8%
FCF Margin
-20,017.3%
Balance Sheet & Liquidity
Current Ratio
2.08x
Quick Ratio
2.08x
Debt/Equity
0.00x
Debt/Assets
45.7%
Interest Coverage
-5,792.95x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T05:12:23.584606 |
Data as of: 2025-12-31 |
Powered by Claude AI